DTL Is a Prognostic Biomarker and Promotes Bladder Cancer Progression through Regulating the AKT/mTOR axis

Table 1

Association between the expression of DTL and clinicopathological characteristics.

Variable	Total patients	DTL expression
	No (%)	Low	High
Age, (years)				0.0003
Age				0.0004
<65	74 (44.8%)	49 (59.0%)	25 (30.5%)
≥65	91 (55.2%)	34 (41.0%)	57 (69.5%)
Gender				0.024
Male	135 (81.8%)	74 (89.2%)	61 (74.4%)
Female	30 (18.2%)	9 (10.8%)	21 (25.6%)
Invasiveness				0.005
Superficial	103 (62.4%)	61 (73.5%)	42 (51.2%)
Invasive	62 (37.6%)	22 (26.5%)	40 (48.8%)
Lymphatic metastasis				0.03
No	149 (90.3%)	79 (95.2%)	70 (85.4%)
Yes	15 (9.1%)	3 (3.6%)	12 (14.6%)
T stage				0.004
Ta	24 (14.5%)	19 (22.9%)	5 (6.1%)
T1	80 (48.5%)	42 (50.6%)	38 (46.3%)
T2	31 (18.8%)	13 (15.7%)	18 (22.0%)
T3	19 (11.5%)	4 (4.8%)	15 (18.3%)
T4	11 (6.7%)	5 (6.0%)	6 (7.3%)
Grade
Low	105 (63.6%)	68 (81.9%)	37 (45.1%)
High	60 (36.4%)	15 (18.1%)	45 (54.9%)